Current Hepatitis Reports

, Volume 4, Issue 3, pp 97-103

First online:

Advances in the treatment of hepatitis C in children and adolescents

  • Valérie A. McLinAffiliated withDivision of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children’s Hospital Medical Center
  • , William F. Balistreri

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Progress is being made in the treatment of hepatitis C virus (HCV) infection in adults. The current recommended strategy is to use the combination of pegylated-interferon and ribavirin, which leads to a sustained virologic response rate in 50% to 60% of individuals eligible for treatment. Less is known about HCV infection in the pediatric population. Recently, small and uncontrolled studies have suggested that combination therapy of interferon alpha with ribavirin improves the outcome of HCV-infected children. There are no data yet regarding the use of pegylated interferons in pediatrics. This article summarizes what is known about the treatment of HCV in children and adolescents, and discusses future areas of research as they may pertain to the idiosyncrasies of the pediatric population.